Effects of Dipeptide Insertions Between Codons 69 and 70 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase on Primer Unblocking, Deoxynucleoside Triphosphate Inhibition, and DNA Chain Elongation

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2003 Mar 1

PMID 12610164

Citations 24

Authors

Peter R Meyer

Johan Lennerstrand

Suzanne E Matsuura

Brendan A Larder

Walter A Scott

Affiliations

Soon will be listed here.

Abstract

Finger insertion mutations of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) (T69S mutations followed by various dipeptide insertions) have a multinucleoside resistance phenotype that can be explained by decreased sensitivity to deoxynucleoside triphosphate (dNTP) inhibition of the nucleotide-dependent unblocking activity of RT. We show that RTs with SG or AG (but not SS) insertions have three- to fourfold-increased unblocking activity and that all three finger insertion mutations have threefold-decreased sensitivity to dNTP inhibition. The additional presence of M41L and T215Y mutations increased unblocking activity for all three insertions, greatly reduced the sensitivity to dNTP inhibition, and resulted in defects in in vitro DNA chain elongation. The DNA chain elongation defects were partially repaired by additional mutations at positions 210, 211, and 214. These results suggest that structural communication between the regions of RT defined by these mutations plays a role in the multinucleoside resistance phenotype.

Citing Articles

A Combination of Amino Acid Mutations Leads to Resistance to Multiple Nucleoside Analogs in Reverse Transcriptases from HIV-1 Subtypes B and C.

Boyer P, Rehm C, Sneller M, Mican J, Caplan M, Dewar R Antimicrob Agents Chemother. 2021; 66(1):e0150021.

PMID: 34723625 PMC: 8765311. DOI: 10.1128/AAC.01500-21.

Avoiding Drug Resistance in HIV Reverse Transcriptase.

Cilento M, Kirby K, Sarafianos S Chem Rev. 2021; 121(6):3271-3296.

PMID: 33507067 PMC: 8149104. DOI: 10.1021/acs.chemrev.0c00967.

Current perspectives on HIV-1 antiretroviral drug resistance.

Iyidogan P, Anderson K Viruses. 2014; 6(10):4095-139.

PMID: 25341668 PMC: 4213579. DOI: 10.3390/v6104095.

HIV-1 reverse transcriptase and antiviral drug resistance. Part 2.

Das K, Arnold E Curr Opin Virol. 2013; 3(2):119-28.

PMID: 23602470 PMC: 4097817. DOI: 10.1016/j.coviro.2013.03.014.

Formation of a quaternary complex of HIV-1 reverse transcriptase with a nucleotide-competing inhibitor and its ATP enhancer.

Ehteshami M, Nijhuis M, Bernatchez J, Ablenas C, McCormick S, De Jong D J Biol Chem. 2013; 288(24):17336-46.

PMID: 23598281 PMC: 3682535. DOI: 10.1074/jbc.M112.433441.

References

Mas A, Parera M, Briones C, Soriano V, Martinez M, Domingo E . Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance. EMBO J. 2000; 19(21):5752-61. PMC: 305792. DOI: 10.1093/emboj/19.21.5752. View

Van Vaerenbergh K, Van Laethem K, Albert J, Boucher C, Clotet B, Floridia M . Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrob Agents Chemother. 2000; 44(8):2109-17. PMC: 90021. DOI: 10.1128/AAC.44.8.2109-2117.2000. View

Boyer P, Sarafianos S, Arnold E, Hughes S . Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J Virol. 2001; 75(10):4832-42. PMC: 114238. DOI: 10.1128/JVI.75.10.4832-4842.2001. View

Masquelier B, Race E, Tamalet C, Descamps D, Izopet J, Buffet-Janvresse C . Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitors. Antimicrob Agents Chemother. 2001; 45(6):1836-42. PMC: 90554. DOI: 10.1128/AAC.45.6.1836-1842.2001. View

Lennerstrand J, Stammers D, Larder B . Biochemical mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to stavudine. Antimicrob Agents Chemother. 2001; 45(7):2144-6. PMC: 90617. DOI: 10.1128/AAC.45.7.2144-2146.2001. View

Lukashov V, Huismans R, Jebbink M, Danner S, de Boer R, Goudsmit J . Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs. AIDS Res Hum Retroviruses. 2001; 17(9):807-18. DOI: 10.1089/088922201750252007. View

Lennerstrand J, Hertogs K, Stammers D, Larder B . Correlation between viral resistance to zidovudine and resistance at the reverse transcriptase level for a panel of human immunodeficiency virus type 1 mutants. J Virol. 2001; 75(15):7202-5. PMC: 114451. DOI: 10.1128/JVI.75.15.7202-7205.2001. View

Isel C, Ehresmann C, Walter P, Ehresmann B, Marquet R . The emergence of different resistance mechanisms toward nucleoside inhibitors is explained by the properties of the wild type HIV-1 reverse transcriptase. J Biol Chem. 2001; 276(52):48725-32. DOI: 10.1074/jbc.M108352200. View

Briones C, Mas A, Perez-Olmeda M, Altisent C, Domingo E, Soriano V . Prevalence and genetic heterogeneity of the reverse transcriptase T69S-S-X insertion in pretreated HIV-infected patients. Intervirology. 2002; 44(6):339-43. DOI: 10.1159/000050068. View

10.

Meyer P, Matsuura S, Tolun A, Pfeifer I, So A, Mellors J . Effects of specific zidovudine resistance mutations and substrate structure on nucleotide-dependent primer unblocking by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 2002; 46(5):1540-5. PMC: 127181. DOI: 10.1128/AAC.46.5.1540-1545.2002. View

11.

Naeger L, Margot N, Miller M . ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 2002; 46(7):2179-84. PMC: 127313. DOI: 10.1128/AAC.46.7.2179-2184.2002. View

12.

de Mendoza C, Gallego O, Soriano V . Mechanisms of resistance to antiretroviral drugs--clinical implications. AIDS Rev. 2002; 4(2):64-82. View

13.

Boyer P, Sarafianos S, Arnold E, Hughes S . Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision. J Virol. 2002; 76(18):9143-51. PMC: 136461. DOI: 10.1128/jvi.76.18.9143-9151.2002. View

14.

Quinones-Mateu M, Tadele M, Parera M, Mas A, Weber J, Rangel H . Insertions in the reverse transcriptase increase both drug resistance and viral fitness in a human immunodeficiency virus type 1 isolate harboring the multi-nucleoside reverse transcriptase inhibitor resistance 69 insertion complex mutation. J Virol. 2002; 76(20):10546-52. PMC: 136580. DOI: 10.1128/jvi.76.20.10546-10552.2002. View

15.

Mas A, Vazquez-Alvarez B, Domingo E, Menendez-Arias L . Multidrug-resistant HIV-1 reverse transcriptase: involvement of ribonucleotide-dependent phosphorolysis in cross-resistance to nucleoside analogue inhibitors. J Mol Biol. 2002; 323(2):181-97. DOI: 10.1016/s0022-2836(02)00911-7. View

16.

Larder B, Chesebro B, Richman D . Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother. 1990; 34(3):436-41. PMC: 171611. DOI: 10.1128/AAC.34.3.436. View

17.

Tan C, Zhang J, Li Z, Tarpley W, Downey K, So A . Functional characterization of RNA-dependent DNA polymerase and RNase H activities of a recombinant HIV reverse transcriptase. Biochemistry. 1991; 30(10):2651-5. DOI: 10.1021/bi00224a013. View

18.

Terai C, Carson D . Pyrimidine nucleotide and nucleic acid synthesis in human monocytes and macrophages. Exp Cell Res. 1991; 193(2):375-81. DOI: 10.1016/0014-4827(91)90110-g. View

19.

Gao W, Cara A, Gallo R, Lori F . Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci U S A. 1993; 90(19):8925-8. PMC: 47473. DOI: 10.1073/pnas.90.19.8925. View

20.

Gao W, Agbaria R, Driscoll J, Mitsuya H . Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2',3'-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem. 1994; 269(17):12633-8. View